This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB03256/identifier/chebi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB03256/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03256/identifier/pdb/
n9http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB03256/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB03256/identifier/pubchem-substance/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n12http://linked.opendata.cz/resource/drugbank/drug/DB03256/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB03256
rdf:type
n3:Drug
n3:description
The active metabolite of FOLIC ACID. Leucovorin is used principally as its calcium salt as an antidote to folic acid antagonists which block the conversion of folic acid to folinic acid. [PubChem]
n3:group
experimental
owl:sameAs
n9:DB03256 n13:DB03256
dcterms:title
5-Formyl-5,6,7,8-Tetrahydrofolate
adms:identifier
n6:15640 n10:FON n11:3033683 n12:DB03256 n14:C03479 n15:46506235
n3:IUPAC-Name
n4:271B5E5D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5E63-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5E62-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5E5F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5E60-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5E61-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5E5B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5E5C-363D-11E5-9242-09173F13E4C5 n4:271B5E59-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5E5A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5E69-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5E6A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5E64-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5E65-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5E67-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5E66-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5E68-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
58-05-9
n3:Bioavailability
n4:271B5E6F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5E71-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5E72-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5E73-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5E6E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5E6D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5E70-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5E5E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5E6B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5E6C-363D-11E5-9242-09173F13E4C5